MAP2K7 and melanoma: A recent clinical trial, conducted on 577 BRAF-mutant melanoma patients, showed that encorafenib alone or in combination with binimetinib (MEK inhibitor) brings benefits, in terms of survival and tolerability, as compared to treatment with vemurafenib alone [7].